Palisade Bio Inc — Cash Flow (NASDAQ:PALI) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -9.03 M-14.77 M-13.36 M-11.13 M-12.19 M-10.85 M -10.85 M Cash from investing activities 0-54 K-10 K-4 0000— — Cash from financing activities 14.47 M24.61 M15.26 M11.19 M9.58 M134.44 M 134.44 M Free cash flow -9.03 M-14.77 M-13.37 M-11.14 M-12.19 M-10.85 M -10.85 M

News

Palisade Bio: Undervalued With Blockbuster Potential, Speculative Buy Rating

Stifel initiates Palisade Bio stock with buy rating on IBD drug

Palisade Bio presents ulcerative colitis drug trial data at ECCO

Palisade Bio appoints IBD expert to clinical advisory board

Palisade Bio appoints two IBD experts to clinical advisory board

Palisade Bio director Williams buys $9,400 in shares

B.Riley initiates coverage on Palisade Bio stock with Buy rating

Crohn’s & Colitis Foundation invests up to $500,000 in Palisade Bio

Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December - GH Research (NASDAQ:GHRS), Momentus (NASDAQ:MNTS)

Palisade Bio receives patent approval in Japan for IBD drug PALI-2108

Palisade Bio stock initiated with Buy rating at Clear Street on IBD drug potential

Alibaba and Tesla among market cap stock movers on Monday